Loading stock data…
DNLI
$19.62-0.09 (-0.46%)
Market ClosedLast close May 8
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Denali Therapeutics Inc. in the Healthcare sector is trading at $19.62. The stock is currently 17% below its 52-week high of $23.77, remaining 11.6% above its 200-day moving average. Technical signals show neutral RSI of 43 and bullish MACD crossover, explaining why DNLI maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.62
Potential Upside
5%
Whystock Fair Value$20.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$35.64+81.7%
Range$25.00 – $42.00
Fundamentals
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflamma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.21B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.25%
Volume
Today's trading volume
1.90M
Recent News
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
This biotech company develops therapies for neurodegenerative and rare diseases, supported by clinical assets and pharma collaborations.
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights
In early May 2026, Takeda informed Denali Therapeutics that it would terminate their collaboration on developing and commercializing DNL593 for business reasons unrelated to the drug’s efficacy or safety, returning full control of the program and its intellectual property to Denali. This shift hands Denali sole ownership of a key neurodegenerative asset built on its TransportVehicle technology, potentially altering how it prioritizes partnerships and internal development across its...
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best Japanese stocks to buy right now. On April 6, Denali Therapeutics said Takeda Pharmaceutical Company Limited (NYSE:TAK) is ending its collaboration on DNL 593. The two companies were working on developing the investigational therapy for frontotemporal dementia caused by granulin gene mutations. The candidate drug […]
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in
Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best biotech stocks with highest upside potential. On April 6, Denali Therapeutics Inc. (NASDAQ:DNLI) revealed that it has received notice from Takeda (NYSE: TAK) about the termination of the collaboration agreement on developing and commercializing DNL593. This move was due to some strategic reasons and is […]
Bernstein Upgrades Takeda Pharmaceutical (TAK) to Outperform
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 10 Stocks to Buy on a Pullback. On April 8, 2026, Bernstein upgraded Takeda Pharmaceutical Company Limited (NYSE:TAK) to Outperform from Market Perform and raised its price target to ¥6,900 from ¥5,100, citing “bold” cost-cutting measures and a series of upcoming pipeline catalysts that could help […]